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ABSTRACT 
Multicomponent biological systems perform a wide variety of functions and are crucially 
important for a broad range of critical health and disease states. A multitude of applications in 
contemporary molecular and synthetic biology rely on efficient, robust and flexible methods 
to assemble multicomponent DNA circuits as a prerequisite to recapitulate such biological 
systems in vitro and in vivo. Numerous functionalities need to be combined to allow for the 
controlled realization of information encoded in a defined DNA circuit. Much of biological 
function in cells is catalyzed by multiprotein machines typically made up of many subunits. 
Provision of these multiprotein complexes in the test-tube is a vital prerequisite to study their 
structure and function, to understand biology and to develop intervention strategies to correct 
malfunction in disease states. ACEMBL is a technology concept that specifically addresses 
the requirements of multicomponent DNA assembly into multigene constructs, for gene 
delivery and the production of multiprotein complexes in high-throughput. ACEMBL is 
applicable to prokaryotic and eukaryotic expression hosts, to accelerate basic and applied 
research and development. The ACEMBL concept, reagents, protocols and its potential are 
reviewed in this contribution. 
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1/ Complex challenge: Functional multigene assembly and delivery 
Multigene delivery into living organisms has taken to center stage in the synthetic biology era 
[1, 2]. This development has been catalyzed by the emergence of powerful technologies to 
precisely assemble DNA pieces representing functional modules into customized 
multifunctional DNA circuits. Recombinant DNA technology emerged half a century ago, 
when so-called ‘restriction factors’ were observed; which inhibited bacteriophage growth in 
bacteria, which turned out to be DNA endonucleases [3-6]. Around this time, DNA ligation 
was discovered as a basis of genetic recombination [7-9], leading to successful assembly of 
DNA fragments [10-14]. Since these ground-breaking discoveries, classical DNA cloning 
involved largely serial steps of cutting and pasting isolated fragments together by using 
restriction enzymes and DNA ligases, into functional DNA molecules (typically plasmids). 
Plasmids containing the DNA insert of choice then were delivered by transformation, 
transduction or transfection into prokaryotic or eukaryotic host cell organisms to exert their 
functions [15]. The advent of the polymerase chain reaction (PCR) enormously advanced the 
field [16], making DNA cloning commonplace in virtually all molecular biology laboratories 
worldwide. Today, DNA assembly has been further accelerated by new and powerful 
technologies, including ligation independent cloning methods (LIC, SLIC) [17, 18], circular 
polymerase extension cloning (CPEC) [19] and seamless ligation cloning extract (SliCE) 
[20], to name a few. For the assembly of very large fragments as precursors of entire 
synthetic genomes, specific cloning methods have been implemented [21]. Concomitantly, 
chemical DNA synthesis is being brought to perfection, considerably increasing the attainable 
size of DNA precursor fragments. These methods are at the core of synthetic biology, a 
vibrant field hailed as a game changer and poised to transform molecular biology and much 
of the life sciences [22-26]. 
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 Molecular cloning has been invaluable to study the structure and function of proteins 
by enabling heterologous expression. Elucidating the sequence content of entire genomes has 
made it possible to address the gene product repertoire - the proteome - of cells and 
organisms. Efficient DNA assembly methods to generate heterologous expression constructs 
have been implemented in concerted ‘omics’ efforts to analyze proteins system-wide, in high-
throughput. Structural genomics consortia were established to determine atomic structures, 
seemingly in an industrial mode [27, 28]. Automation and robotics have become a 
prerogative; as a consequence, traditional cloning methodologies were progressively replaced 
by more advanced methods [1, 29-32]. A large number of vital functions in cells are mediated 
by multiprotein complexes composed of several to many subunits, and the function of a 
particular catalytic unit is often determined by its interaction partner(s). This has profound 
consequences for our understanding of the molecular mechanisms that are at the basis of 
biology. At the same time, this also imposes additional requirements on DNA assembly 
technology to support recombinant expression of complexes in high-throughput.  
The ACEMBL technology was conceptualized to meet these requirements, to enable 
structural and functional “complexomics” research and discovery [31-34]. ACEMBL 
comprises recombination-based assembly of DNA elements into functional multigene 
expression constructs that can be rapidly permutated in a combinatorial fashion [33].  
Originally, ACEMBL was developed for combinatorial multiprotein production in E.coli as a 
prokaryotic expression host [33]. Subsequently, efficient ACEMBL tool-kits have been 
developed also for multigene expression in eukaryotic hosts [34-37]. The integration of the 
ACEMBL technology in MultiBac, currently the lead technology for multiprotein complex 
production in insect cells, is described in a dedicated contribution of this issue [37]. The 
present overview therefore has as its focus the impact of ACEMBL on bacterial and 
mammalian multigene transfer applications. 
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2/ ACEMBL: Automated unrestricted DNA recombineering for multigene delivery 
Our knowledge of cellular processes have enormously advanced, brought about by an array 
of recent technological developments, notably in affinity purification, DNA sequencing, mass 
spectroscopy, yeast two-hybrid screens and computational approaches [38]. These 
technological developments compellingly validated the notion that virtually all essential 
cellular processes (DNA replication, transcription, translation, cell cycle regulation, 
intermediary metabolism, many more) are catalyzed by a highly coordinated network of 
protein-protein interactions, in which most proteins collaborate and function in the context of 
multiprotein complexes, underpinning the notion of ‘protein sociology’ in the cell [39].  
Detailed structural and functional analysis is indispensable for elucidating the 
biological functions of these highly complex networks. Knowledge of molecular architectures 
can form the basis of intervention strategies, for example, to correct malfunction in disease 
states by supplying structure-based, custom-designed chemical compounds. Recapitulation of 
physiological interdependencies in the test-tube is a critical prerequisite for designing such 
compounds, and also for their preliminary validation by biochemical, biophysical and 
pharmacological means. Most multiprotein complexes, particularly those in humans, exist in 
(very) low endogenous amounts and are furthermore often heterogeneous in their 
composition, which is typically refractory to their extraction from native or cultured cell 
material. Heterogeneity in post-translational modifications, which may be essential for 
exerting the full activity of a given complex, can further limit the utility of material obtained 
from endogenous source.  
Recombinant production offers solutions to these impediments, and a wide range of 
expression systems are available to produce proteins recombinantly in prokaryotic and 
eukaryotic hosts [31, 33, 34-45]. Recombinant expression systems share in common that one 
or several DNA segments encoding for proteins, protein domains or multicomponent protein 
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complexes are typically combined with DNA elements including DNAs that control 
transcription (promoters, terminators, others) and translation (ribosome binding sites, Shine-
Dalgarno sequences, Kozak consensus sequences, enhancers, others) and inserted into a 
functional DNA module (plasmid, cosmid, artificial chromosome, genome, others). The 
resulting construct is then used to deliver the DNA segments of interest to host cell organisms 
by means of transformation, transfection or transduction.     
 The underlying technologies were perfected over the years to a level that they could 
be productively harnessed in ambitious, highly parallelized ‘omics’ programs aimed at 
genome- and proteome wide studies of proteins in many organisms including humans [28]. In 
these research undertakings, protein encoding genes are synthesized, manipulated, varied and 
delivered into recombinant expression hosts on an industrial scale to enable high-throughput 
structure determination, populating protein structure databases such as the protein data bank 
(PDB) with unmatched efficiency and breathtaking speed, ushering in a new age of protein 
structural and functional research.   
 Initially, these efforts were focused on single proteins, protein domains or small 
assemblies of two, maximally (rarely) three interactors. Our more recent understanding that 
the activity of a given protein catalyst can be decisively influenced by the (sometimes many) 
partners that arrange in multicomponent assemblies has to a certain degree challenged this 
minimalist approach. It is legitimate to postulate that, if proteins in cells act as parts of large 
and complex assemblies, then they should also be studied in vitro in the form of such large 
complexes, with a full complement of binding partners present. This approach offers 
opportunities and advantages, notably for drug discovery in pharma and biotech, where 
‘being close(r) to physiological’ can be a tremendous asset. Evidently, however, it also 
complicates the experimental approach quite significantly, posing substantial technical 
challenges. 
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 A multigene delivery system that affords to establish physiologically meaningful 
contexts ex vivo needs to be simple to use, robust, efficient and ideally compatible with 
automation and robotics, and readily accessible if similar breakthroughs for multiprotein 
complexes are to be achieved as have been successfully made already for single proteins and 
protein domains. We have taken advantage of more recent advances in DNA synthesis and 
molecular cloning technologies to develop ACEMBL, a technology concept that in our view 
successfully addresses these challenges [33]. ACEMBL exploits sequence and ligation 
independent multifragment cloning technology combined with site-specific multicomponent 
recombination for unrestricted assembly of multigene delivery constructs in a combinatorial 
fashion that is readily amenable to robotics [33, 46]. Affordable and efficient chemical 
synthesis methods of large DNAs as precursor molecules further potentiate the utility of 
ACEMBL for a broad range of applications. 
2.1/ ACEMBL DNA design 
The ACEMBL system utilizes a series of custom-designed vectors (called Acceptor or 
Donor, respectively) for multigene vector generation catalyzed by Cre-LoxP recombination 
[33, 34, 44, 46, 47]. All ACEMBL vectors are scratch-built, synthetic small plasmids (2-3 
kilobases). Acceptor and Donor plasmids exclusively contain the minimal DNA elements 
absolutely required for protein expression and plasmid propagation, in addition to a set of 
DNA elements required for multigene assembly. In contrast to conventional expression 
plasmids including most commercial plasmids, these elements are directly juxtaposed, 
without intervening sequences devoid of functionality, giving rise to the smallest possible 
DNA molecules that propagate and can be used for multigene expression (Fig. 1). 
 ACEMBL plasmids contain common modules such as promoter / terminator and 
resistance marker. The Multiple Integration Element (MIE), adapted from a previously 
published polylinker [33], is tailored to support single or multiple gene insertions via 
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conventional restriction / ligation methods or, preferably, sequence and ligation independent 
cloning (SLIC) [33, 46] (Fig. 2). In addition, complementary homing endonuclease (HE) / 
BstXI site pairs are introduced for theoretically unlimited iterative gene insertions. We 
usually insert DNAs (genes of interest or fragments) that are chemically synthesized in the 
given format of choice, eliminating undesired restriction sites (including HE, BstXI) in the 
process.  
 There are two origins of replication in ACEMBL tool-kits; Acceptors contain a 
common E.coli origin of replication (BR322) and Donors contain a conditional origin of 
replication derived from phage R6Kγ. All plasmids contain a different resistance marker. 
Acceptors and Donors shown in Figure 1 contain elements that are specific for multigene 
delivery and expression in E.coli as a prokaryotic host. Similar Acceptors and Donors have 
been developed for multigene delivery and multiprotein complex expression in eukaryotic 
hosts, retaining the backbones but containing customized DNA elements (promoter / 
terminator pairs, gene integration sites, homologous recombination sequences, others) 
required in the respective eukaryotic host organisms (mammalian and insect cells).  
2.2/ Multigene assembly by Tandem Recombineering (TR) 
The SLIC reaction, in marked contrast to conventional cloning relying on restriction enzyme 
mediated digestion and ligation, can be readily scripted into a robotics routine [33]. 
ACEMBL Acceptor and Donor plasmids that contain one or several genes each are then 
concatamerized for multigene co-expression in a rapid and flexible fashion, by utilizing the 
LoxP imperfect inverted repeat sequences present on each plasmid, and the Cre recombinase 
which fuses LoxP sequences in a site-specific recombination reaction (Fig. 3) [48, 49]. 
Tandem Recombineering (TR) is the combination of SLIC-mediated gene integration and 
Cre-LoxP Acceptor-Donor fusion [46]. 
9 
 
 When educt DNAs containing single LoxP sites are subjected to Cre-LoxP 
recombination, only a small portion of educt DNAs are combined together, while the rest 
remain separate and co-exist with the fusion products. Acceptors contain a regular origin of 
replication (BR322), which enables their replication in regular E. coli strains (TOP10, 
OmniMAX, BL21, etc). In contrast, Donors contain a conditional origin of replication termed 
R6Kγ (the γ replication origin of the R6K plasmid) [50]. The replication of Donors requires 
the presence of the π protein (encoded by pir gene) in the host cell. Therefore, propagation 
and manipulation of all Donors has to be carried out in specific E. coli strains, which contain 
a pir gene inserted into their genome. Donors cannot replicate in a regular E. coli strain, 
which does not contain the pir gene (i.e. pir-negative), unless fused with an Acceptor with a 
regular origin of replication. Thus, the recombination of Acceptors and Donors can be 
exploited for specific selection of desired fusion products.  
 A single Acceptor could be recombined in a single Cre-LoxP reaction with a 
theoretically unlimited number of Donors, with one to several expression cassettes on each 
Donor and Acceptor. Pragmatically, we use one Acceptor and up to three Donors to generate 
multigene constructs for heterologous expression. Due to the equilibrium nature of the Cre-
LoxP reaction, the recombination reaction products are a mixture of all possible fusions from 
two or more educts, including Acceptor-Acceptor, Acceptor-Donor, and Donor-Donor 
fusions. Since excision is favored, fusion products containing increasing numbers of educts 
are present in decreasing amounts. All fusion products and also the single educt plasmids are 
quasi bar-coded by their characteristic resistance marker combinations (Fig. 4), as all 
plasmids of the system have a different resistance marker. After transformation into regular 
E.coli strains (pir-negative background), all unwanted Donors and Donor-Donor fusions are 
eliminated since their conditional origins are inactive in pir-negative E.coli strains, while the 
desired Acceptor-Donor fusions are selected by challenging with corresponding combinations 
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of antibiotics (Fig. 4). This enables the tailored generation of multigene vectors expressing a 
complete protein complex as well as subsets of its subunits, in a single Cre-LoxP reaction. 
This combinatorial approach is instrumental for investigating the hierarchical assembly of 
multiprotein complexes, the biological functions of specific subunit(s) or their combinations, 
as well as the integration of putative subunit isoforms into a multiprotein complex of choice 
[31]. Thus selected arrays of fusion plasmids can then be used for gene delivery into 
expression host cells, optionally in high-throughput. 
 Subsequent to antibiotic challenge, fusion plasmids can (and probably should) be 
verified by restriction mapping. For example, transformants might contain fusion products 
harboring more than one copy of a particular educt vector. This can be potentially detrimental 
by causing expression level imbalance between subunits due to the increase in copy number 
of the gene(s) present on the particular educt. On the other hand, this could also be used to the 
benefit of the expression experiment. When a certain gene of interest is expressed at lower 
levels as compared to other genes in a multigene expression experiment, it can be helpful to 
incorporate an additional copy of the corresponding educt plasmid, and/or to place the same 
gene in several copies on one or more educt plasmids prior to the Cre-LoxP fusion reaction.  
 When more than two educt vectors are subjected to Cre-LoxP recombination, their 
incorporations are stochastic and thus lead to sequence variations in the fusion plasmids 
depending on the assembling orders of educt vectors (Fig. 5). The number of possible fusion 
plasmids (Pn) containing n educt vectors (each as a single copy) is given by the formula of 
circular permutation:
)!1( -= nPn . For example, a fusion plasmid containing one acceptor and 
three donors (n=4) has 6!34 ==P  possible variants (Fig. 5). From our experience, the order 
of assembly of educts in a multifusion plasmid apparently does not prejudice the success of a 
complex expression experiment. Nonetheless, good practice requires verifying the order of 
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assembly of educts in the multifusion plasmid as a quality control step. Therefore, the exact 
DNA sequences of all possible fusion variants are required for verification and selection by 
restriction digestions. To facilitate the in silico generation of DNA sequences of all possible 
fusion variants, we programmed a software application, Cre-ACEMBLER [51, 52].  
2.3/ Cre-ACEMBLER software 
Cre-ACEMBLER was programmed in Python and runs on Windows, Linux, and MacOS 
operating systems. Cre-ACEMBLER displays sequence data in an application window, 
showing the sequence as plain text. Simple manipulations can be done using cut, copy and 
paste functions. Sequence data can be read from and written to files in various formats, 
including FASTA and GenBank.  
 To perform in silico Cre recombinations, all educt plasmid sequences have to be 
opened in Cre-ACEMBLER. Activating the “Cre” button starts an assistant dialogue guiding 
through the recombination in three steps: (1) Acceptor plasmid sequence is selected among 
all open sequences; (2) Donor plasmid sequences are selected; (3) Adjustment of the desired 
copy numbers of each individual plasmid.  Each possible product sequence is then generated 
and displayed in a new window. Product sequences can then be saved to files and analyzed 
using other software, e.g. ApE [53] or Vector NTI [54]. Prerequisites to be fulfilled by Cre-
ACEMBLER were ease of use, compatibility with a broad range of operating systems and 
interoperability with other software. No central processing unit (CPU)-intensive work is done 
by Cre-ACEMBLER, thus an interpreted programming language could be chosen without 
risking performance limitations. Therefore, Cre-ACEMBLER was developed in Python [56], 
using the Python bindings of GTK+ [57, 58] for the graphical user interface, and the 
Biopython [59] library for sequence data manipulations. Using Python and GTK+ allows 
Cre-ACEMBLER to run on Windows, Linux and MacOS operating systems, and possibly 
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others. The Biopython library allows reading and writing sequence data in various file 
formats, providing good interoperability with other software.  
  It is of advantage for the in silico Cre recombination if LoxP sites in all input (educt) 
sequences are in the same orientation, and if the linear representation of each input sequence 
starts with the LoxP site. Therefore, all input sequences are normalized prior to 
recombination, by generating the reverse-complement of input sequences if required, and by 
linearizing all sequences immediately 5' of the LoxP site. All input sequences are then 
indexed numerically, making sure that identical input sequences get the same index. Lists 
representing all possible permutations of the order of the indices are computed, and redundant 
solutions (if considering circular arrangement) are eliminated, thus yielding index lists 
representing only unique circular permutations. Fusion plasmid sequences are then generated 
from these index lists by appending the normalized input sequences corresponding to the 
indices, in the order given in these lists.  
 A challenge arising from the linear representation of circular sequences is to identify 
permutations which are redundant if circular arrangement is considered. In order to make the 
lists representing different circular arrangements comparable, a linearization algorithm had to 
be found which transforms a linear representation with a random starting point reliably into a 
linear representation with a defined starting point. To accomplish this, the lowest index in the 
lists is taken as a potential starting point for linearization. If several instances of this lowest 
index are present in the list, each instance is credited a score according to the subsequent 
indices in the list. The instance that is followed by the highest count of lowest indices gets the 
highest score, and the list is rearranged such that this instance becomes the first entry. Lists 
transformed in this way can then simply be compared using Python's equality operator, so 
that redundant solutions can be identified and eliminated.  
13 
 
 Cre-ACEMBLER has proven to be a valuable, robust tool in extensive testing by 
users of the Eukaryotic Expression Facility (EEF) at EMBL Grenoble, proving the reliability 
of the algorithms described above. Cre-ACEMBLER is freely available for download [51]. A 
Cre-ACEMBLER User Manual is likewise available on-line [52]. 
3/ ACEMBL applications  
The ACEMBL system was first introduced for robotized production of multiprotein 
complexes in high-throughput [33]. Subsequently, the ACEMBL pipeline was extended to 
eukaryotic expression systems (Fig. 6) in order to produce functional eukaryotic protein 
complexes requiring the authentic processing and post-translational machinery provided by 
eukaryotic hosts [31]. Multifusion plasmids generated from Cre-LoxP reactions are utilized 
by the ACEMBL-derived MultiMam system to facilitate simultaneous multigene introduction 
into mammalian cells [35, 36] (see also 3.2). The MultiBac baculovirus / insect cell system 
has been upgraded for robotics by incorporating ACEMBL DNA modules (MIE and HE / 
BstXI sites) for automatable and theoretically unlimited multigene insertion into a baculoviral 
genome for protein co-expression in insect cells [34] (see also Chapter on MultiBac by Sari 
and co-workers in this issue). Selected examples of ACEMBL applications are highlighted in 
the following. 
3.1/ ACEMBLing DNA for structural and molecular biology 
ACEMBL has been used successfully for a variety of applications in structural and molecular 
biology. Numerous multisubunit complexes, including soluble multiprotein complexes, 
protein-RNA complexes and multimeric membrane protein complexes have been produced 
successfully by ACEMBL [33, 44, 60-64]. Examples include the prokaryotic signal 
recognition particle, SRP, the catalytic cycle of which is being studied by cryo-electron 
microscopy and biochemical means [60-62]. A particular highlight is the prokaryotic holo-
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translocon complex (HTL), a seven subunit transmembrane multiprotein assembly consisting 
of the heterotrimeric core translocon, SecYEG, and its accessory proteins SecD, SecF, YidC 
and YajC. HTL is a long elusive complex that was, for the first time, successfully produced 
recombinantly by ACEMBL [63, 64]. HTL catalyzes the transport of protein substrates 
through and into membranes, making use of the proton motive force (PMF) [63]. Moreover, 
ACEMBL was applied to reveal the substrate specificity for interferon-stimulated gene 15 by 
ubiquitin-specific protease 18 [65]. Many research laboratories have already obtained 
ACEMBL reagents, and ACEMBL systems are in the process of being integrated into 
structural genomics pipelines. We expect in the coming years numerous more exploits 
brought about by our multigene delivery technologies, and we anticipate productive synergies 
with other multigene recombineering tools, to deconvolute internal redundancy and explore 
functional structure in complex biological systems [66-69]. 
3.2/ Highly efficient multigene delivery in mammalian cells 
We implemented TR to facilitate rapid generation of multicomponent gene expression 
circuits from Acceptors and Donors containing mammalian cell active promoters [35, 36] 
(Fig. 6). These multicomponent circuits are used for efficient multigene delivery in 
mammalian cells, resulting in homogeneous cell populations [35]. Such results could not be 
obtained previously by classical methods relying on co-transfection of plasmids modules. 
Using fluorescently labelled proteins to visualize mammalian cell compartments, their 
substructures and contents is a common technology in cell biology and pharmacological 
applications. Homogeneous cell populations are a prerequisite for monitoring perturbations of 
cell states, biological processes, metabolic pathways, signaling cascades and the effect of 
additives, for example in high-content screening. The utility of the TR approach to generate 
homogeneous cell populations by multigene delivery of fluorescently labelled proteins was 
compellingly demonstrated using pig cardiac endothelial cells that expressed five different 
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proteins, delivered by a TR construct fitted with mammalian cell active promoters [35]. A 
constant relationship between expression levels of the proteins at the level of individual cells 
was demonstrated [35]. Moreover, this approach was applied to analyze the localization of 
epidermal growth factor receptor (EGFR) with Ran GTPases in endosomal trafficking, and to 
demonstrate how Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles, 
thereby specifying signal output [35, 70].  
We anticipate that a wide range of applications will benefit from a synchronized 
delivery of multiple genes. Our innovative approach has the potential to facilitate the 
production of multicomponent protein drugs including next-generation vaccine candidates 
such as virus-like particles. Multiplexed labelling of living cells, protein-protein interaction 
studies, the construction of designed gene regulatory circuits and entire synthetic signalling 
cascades are further active research and development fields that could benefit from ACEMBL 
technologies. 
4/ Metabolic engineering 
Metabolic engineering is emerging as an overarching concept subsuming a collection of 
methods and concepts for re-directing, improving or modifying cellular and organismal 
biochemical pathways, with the goal of generating novel qualities. At the core of synthetic 
biology, metabolic engineering has been defined as “the purposeful modification of cellular 
activities with the aim of strain improvement” [71]. A purpose is to achieve an overall higher 
productivity and superior quality of scientifically or commercially interesting molecules in 
research and development, and in industrial settings. These can include proteins, protein 
complexes, nucleic acids, biochemicals and metabolites that normally do not accumulate to a 
significant degree or sufficient quality, and would otherwise have to be chemically 
synthesized or extracted from natural sources. Moreover, complex chemical structures, for 
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instance with multiple chiral centers, often are easier produced in engineered microorganisms 
or cells, at lower cost. 
Researchers wish to tweak the host which is the organismal “factory”, by altering its 
biological traits, to produce modified or new substances [72]. Such refinements require 
considerable genetic engineering for custom-design of entire regulatory circuits and 
metabolic pathways and their efficient delivery into the host organism. Concurrently, 
‘negative’ factors need to be removed, which would otherwise be detrimental to achieving the 
desired product yields and quality improvements. For example, production strains may need 
to be made more resilient to demands incurred by (multi)protein overexpression [73]. 
Physiological knowledge of the pathways under investigation, choice of the right production 
organism, information from metabolic flux modelling and bioprocess development need to be 
considered and addressed in the design of the synthetic multifunctional DNA circuits to be 
delivered [74]. This can then be exploited for the improved production, up to fermenter scale, 
of protein therapeutics such as monoclonal antibodies, commodity chemicals such as 
vitamins or rare amino acids, valuable metabolites, biomolecules eliciting fragrances and 
flavors, rare natural (medicinal) compounds (such as artemisinin and taxol) or even biofuel 
production [74-78]. While some constraints can be overcome by optimizing culture 
conditions, others can more successfully be tackled by modifying defined metabolic 
pathways. A thorough knowledge of the cellular biochemistry in conjunction with new and 
powerful recombinant DNA technology now allows “to rationally modify and design 
metabolic pathways, proteins, and even whole organisms.” [78]. 
Biosynthetic pathways can now be (re)constructed from scratch and adapted to a host 
organism to either replace or complement endogenous pathways [75, 79]. Genetic 
modifications involved include for example plugging in appropriate regulatory elements into 
the plasmid constructs, optimizing codon usage or transcription factor activity, and tuning the 
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effects of intergenic regions. At the same time, endogenous pathways can be shut down or 
reduced [80] to optimize the balance between heterologous and endogenous biochemical 
activities [79]. Side effects or roadblocks encountered can be ameliorated or removed by 
multiple rounds of engineering [79, 81, 82].  
ACEMBL tool-kits, due to unmatched flexibility and robustness, in our view may be 
optimally suited to address these manifold requirements for building multifunctional 
heterologous expression constructs, predominantly to equip E.coli, insect and mammalian 
cells with multiple genes and functionalities, combinatorially arranged by TR in 
multicomponent DNA regulatory circuits. An advantage of ACEMBL is that individual (sets 
of) components can be distributed on several plasmid modules (Acceptors and multiple 
Donors) and recombined as desired. Furthermore, individual (sets of) components can be 
flexibly modified without compromising other (sets of) components, and new components 
introduced if required. Moreover, gene regulatory elements including promoters and 
terminators can be altered or tuned with ease, and adapted to the host organism and the 
specific requirements of the target molecule(s).  
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5/ Conclusion 
The ACEMBL technology concept was originally conceived to synergistically address two 
sets of requirements. On the one hand, we intended to create technologies that assist in 
making hitherto inaccessible target molecules, in particular multiprotein complexes, 
amenable to high-resolution structural and functional analysis as a prerequisite to better 
understand their cellular activities, and to enable their modulation for example if malfunction 
occurs in disease states. On the other hand, we wanted our technologies to be sufficiently 
robust to facilitate automation and robotics, to harness the benefits of parallelized workflows 
that already have been established for high-throughput applications with remarkable success. 
ACEMBL fulfills these requirements, and we are hopeful that the methods we developed will 
contribute significantly to the system-wide elucidation of the protein ‘complexome’ of cells 
and organisms, in health and disease. Currently, ACEMBL reagents are available for 
multigene delivery and heterologous expression in E.coli, mammalian cells and insect cells as 
hosts, and further systems targeting other important organismal factories are forthcoming. 
Moreover, beyond heterologous protein complex production, ACEMBL holds significant 
promise to catalyze synthetic biology approaches which are at the forefront of current 
biology, by enabling multiplexed assembly of synthetic multicomponent DNA constructions 
for highly efficient multigene delivery, in prokaryotic and eukaryotic hosts, for a wide range 
of applications. 
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Figures Legends 
Figure 1. ACEMBL technology concept. (A) Acceptor and Donor plasmids are shown in a 
schematic view (top). The examples shown here are used for multigene delivery in E.coli as 
an expression host. Acceptor and Donor vectors contain a LoxP sequence and an identical 
Multiple Integration Element (MIE). Promoters (T7 or lac), corresponding terminators and 
homing endonuclease (HE) sites (blue strike-through box, Acceptors: I-CeuI; Donors: PI-
SceI) and matching BstXI sites (small blue squares) are indicated. Origins of replication 
(Acceptors: BR322; Donors: R6Kγ) are shown. Ap: Ampicillin, Tet: Tetracycline, Cm: 
Chloramphenicol, Kn: Kanamycin, Sp: Spectinomycin. The Multiple Integration Element 
(MIE) is specific for expression in a prokaryotic host and supports assembly of polycistrons 
encoding for several genes controlled by a single pair of promoter and terminator. (B) Outline 
of the method (adapted from [33]). 
Figure 2. Gene insertion into ACEMBL Acceptors and Donors by SLIC. Gene insertion 
into ACEMBL plasmids by sequence and ligation independent cloning (SLIC) is shown in a 
schematic representation. Primer DNA oligonucleotides used for PCR are shown as thin bars 
with arrows. RBS stands for ribosome binding site. 5’ denotes the five-prime end. Regions of 
homology in the Multiple Integration Element (MIE) are shown as boxes filled in gray. 
Single gene integration is shown on the left. Multigene integration yielding a polycistron is 
depicted on the right. PCR stands for polymerase chain reaction. Exonuclease treatment is 
conveniently performed by T4 DNA polymerase in the absence of deoxyribonucleotide 
triphosphates (dNTPs) (adapted from [33]). 
Figure 3. Cre-LoxP fusion reaction. Mechanism of Cre-mediated DNA fusion is shown in a 
schematic representation. Cre enzyme (shape filled in gray) recognizes LoxP sites (marked 
by dashed lines and arrow) present on DNA molecules and fuses them in an equilibrium 
reaction favoring excision (left). The sequence of the LoxP imperfect inverted repeat is 
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displayed (top, right). Cre-LoxP mediated fusion is a one-step reaction requiring a simple 
protocol that can be automated. The structure of four copies of Cre enzyme bound to a 
Holliday junction reaction intermediate is shown in the inset (adapted from [49]).  
Figure 4. ACEMBL combinatorics. Dynamic assembly (Cre) and disassembly (De-Cre) of 
Acceptor and Donor plasmids by Cre-LoxP reaction is shown schematically (top). LoxP sites 
are drawn as red circles, resistance markers and origins of replication are colored as above 
(Fig. 1). White thick arrows denote expression cassettes. AD stands for Acceptor-Donor 
fusion. ADD stands for Acceptor-Donor-Donor fusion. Not all possible fusion products are 
shown for clarity. Levels of multiresistance for product selection are indicated (top, right). 
All reactions occur in a single Eppendorf tube. Fusion products co-exist with educts. 
Productive fusion products are selected using (multi)antibiotic challenge, for example on a 
96-well micro-titer plate (bottom). Desired Acceptor-Donor fusions are identified according 
to their resistance marker ‘bar-code’. Color-coding of antibiotics is listed (bottom, right). LB 
stands for Luria-Bertani / lysogeny broth.  
Figure 5. Acceptor-Donor fusion arrays. Variants of possible multifusion plasmids are 
depicted, containing two (top row), three (middle row), or four (bottom row) educt plasmids 
(Acceptor, Donors), each as a single copy. Box filled in red denotes Acceptor (A), Boxes 
filled in green, blue and purple denote three Donors (D1, D2 and D3, respectively). The 
linear order (starting with A for simplicity) of educts in each (circular) multifusion plasmid is 
indicated below the corresponding plasmid map. The number of educt vectors and 
compositions are indicated (right). 
Figure 6. ACEMBL tool-kits (as of 2014). Prokaryotic and eukaryotic expression systems 
derived from ACEMBL technology for multiprotein co-expression (adapted from [31]).  Note 
that initially, ACEMBL referred to the E.coli system. We have now named the individual 
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ACEMBL systems MultiColi for E.coli, MultiMam for mammalian and MultiBac for 
baculovirus/insect cell expression. 
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Figure 1. ACEMBL technology concept. 
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Figure 2. Gene integration in ACEMBL Acceptors and Donors by SLIC.  
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Figure 3. Cre-LoxP fusion reaction.  
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Figure 4: ACEMBL combinatorics. 
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Figure 5. Acceptor-Donor fusion arrays. 
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